Ted Buchan & Co’s AbbVie ABBV Stock Holding History

Ted Buchan & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$345K	Hold	1,587	–	–	0.13%	68
2025 Q4	$363K	Sell	1,587 -13	-0.8%	-$2.96K	0.13%	71
2025 Q3	$370K	Buy	1,600 +13	+0.8%	+$2.65K	0.15%	67
2025 Q2	$295K	Hold	1,587	–	–	0.12%	83
2025 Q1	$333K	Hold	1,587	–	–	0.16%	71
2024 Q4	$282K	Hold	1,587	–	–	0.13%	78
2024 Q3	$313K	Hold	1,587	–	–	0.15%	74
2024 Q2	$272K	Hold	1,587	–	–	0.15%	75
2024 Q1	$289K	Hold	1,587	–	–	0.18%	76
2023 Q4	$246K	Sell	1,587 -45	-3%	-$6.56K	0.18%	74
2023 Q3	$243K	Hold	1,632	–	–	0.2%	68
2023 Q2	$220K	Hold	1,632	–	–	0.17%	77
2023 Q1	$260K	Buy	1,632 +80	+5%	+$12.2K	0.22%	65
2022 Q4	$251K	Buy	+1,552	New	+$238K	0.23%	63

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ted Buchan & Co's ABBV Position: Q1 2026 in Review

Ted Buchan & Co held its AbbVie (ABBV) position steady in Q1 2026 at 1,587 shares worth $345K. The position accounts for 0.13% of the portfolio, ranked #68.

Ted Buchan & Co first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $370K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ted Buchan & Co held 1,587 shares of AbbVie worth $345K as of Q1 2026.
Ted Buchan & Co left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.13% of Ted Buchan & Co's portfolio in Q1 2026, its #68 holding.
Ted Buchan & Co first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Ted Buchan & Co's AbbVie position peaked at $370K in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ted Buchan & Co's 13F filing for Q1 2026, filed 14 May 2026.